The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
New Stories
-
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News -
Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy
December 15, 2025 - - Australian Biotech -
Prescient secures European approval to launch PTX-100 trial for rare lymphoma
December 15, 2025 - - Australian Biotech -
Orthocell lodges European and UK regulatory application for Remplir
December 15, 2025 - - Australian Biotech -
Neuren wins second FDA approval for trofinetide with launch of formulation
December 15, 2025 - - Australian Biotech -
Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200
December 15, 2025 - - Australian Biotech -
Radiopharm Theranostics reports high success rate in Phase 2b imaging trial
December 15, 2025 - - Australian Biotech